ArticleFrontiers in cellular and infection microbiology2011
Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?
Article in Frontiers in cellular and infection microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association).Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023Guideline
- Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.The Cochrane database of systematic reviews · 2020Pooled it
- Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.The Cochrane database of systematic reviews · 2016Pooled it
- Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.Infection · 2026Review
- Glycoproteomic and proteomic analysis ofMicrobiology spectrum · 2024Article
- Review
- Phage therapy to treat cystic fibrosisFrontiers in microbiology · 2024Review
- Cefiderocol to manage chronic, multi-drug-resistantAccess microbiology · 2022Article
- Molecular Characterization of theAntibiotics (Basel, Switzerland) · 2020Article
- Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study.BMC pulmonary medicine · 2020Article
- Loss ofmSphere · 2019Article
- Article
- Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.BMC pulmonary medicine · 2018Article
- Antimicrobial activity of essential oils against multidrug-resistant clinical isolates of the Burkholderia cepacia complex.PloS one · 2018Article
- Investigating the Mechanism of Action of Diketopiperazines Inhibitors of theFrontiers in pharmacology · 2018Article
- Cystic Fibrosis: Microbiology and Host Response.Pediatric clinics of North America · 2016Review
- Burkholderia cepacia complex in Serbian patients with cystic fibrosis: prevalence and molecular epidemiology.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Article
- Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.BMC pharmacology & toxicology · 2016Article
- Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms.Drugs in R&D · 2016Review
- One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.Clinical medicine insights. Pediatrics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOrganisms of the Burkholderia cepacia complex (BCC) are important pathogens in cystic fibrosis (CF). The majority of those who acquire BCC develop chronic infection but it can also result in rapid decline in a significant minority. In addition, chronic infection with Burkholderia cenocepacia in particular is regarded as a contraindication to lung transplantation in many units. Whilst aggressive antibiotic therapy is employed in CF to eradicate Pseudomonas aeruginosa before infection becomes irreversibly established, no formal assessment of such strategies has been previously reported for BCC, despite the apparent widespread adoption of this practice.
methodsUK adult CF centers were surveyed about their current approach to new BCC infection. Outcomes of eradication therapy were assessed in patients attending the Manchester Adult CF Center with new BCC isolates between 1st January 2002 and 1st May 2011. Patients with previous infection with the same strain of BCC were excluded. BCC were identified at the national reference laboratories and confirmed by species-specific PCR and RecA sequencing.
resultsRoutine use of therapies to attempt eradication of new BCC is commonly used in the UK (12/17 centers who responded). This typically involves a combination of intravenous and nebulised antibiotics. Of 19 eligible cases of new BCC infection, the organism has been eradicated in 7 (37%). Three of these did not receive specific eradication therapy. Of 14 patients who have received eradication therapy and completed follow up, BCC were cleared in only 4 (29%).
conclusionsAttempted eradication of new BCC is a common practice in UK adult CF centers. A minority of patients clear the infection spontaneously and the effects of eradication therapies are at best modest. Early treatment may be associated with better outcomes, though there are insufficient data to support the use of any specific treatment regimen. A prospective, systematic evaluation of treatments and outcomes is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.